Sermorelin

Research Overview

Sermorelin is the GHRH(1-29) peptide with the deepest pharmacological literature, which makes it a reference compound for the GHRH receptor. Common research directions include:

• GHRH-receptor signalling and pituitary somatotroph responsiveness
• Pulsatile versus continuous GH-release dynamics
• GHRH receptor signalling and downstream IGF-1 expression
• Benchmarking against modified analogues such as CJC-1295 and tesamorelin

Why the GHRH(1-29) Fragment is Enough

Native GHRH is 44 amino acids long, but its activity is concentrated in the N-terminal segment:

• Residues 1-29: receptor binding and full biological agonist activity
• Residues 30-44: dispensable for receptor activation, with a possible role in molecular stability

Because the 1-29 fragment retains full potency at the GHRH receptor, sermorelin behaves as a functional equivalent of full-length GHRH while being far simpler to synthesise as a research peptide.

Pulsatile Release and Somatostatin Feedback

The short ~7-12 minute half-life is a feature of the native sequence:

1. The hypothalamus normally releases GHRH in pulses across the day
2. Between pulses, somatostatin (SRIF) tone suppresses GH release
3. Sermorelin, like native GHRH, acts mainly during the low-somatostatin windows
4. GH release therefore stays subject to somatostatin feedback

Storage

Lyophilised vials: store at -20°C, protected from light.

For research purposes only. Not for human consumption.